A preclinical study on IMMU-130—an ADC that targets CEA—revealed that the ADC efficiently reduced tumor growth in a mouse xenograft model implanted with LS174T human CRC cells [118,119]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.